Literature DB >> 3883219

Fibrous mass complicating epidural morphine infusion.

B A Rodan, F L Cohen, W J Bean, S N Martyak.   

Abstract

The benefits of continuous epidural morphine infusion using an implanted pump delivery system to control intractable cancer pain have recently been described. Most articles on this subject relate to dosage, technique, degree of pain relief, and tolerance. There are some anticipated complications of the treatment related to the surgical implantation of the system and drug toxicity. We present a complication presumably related to the epidural catheter. A fibrous reaction that developed around the catheter tip progressed into a mass. This caused a significant displacement of the spinal cord with the development of long tract symptoms. Identification of this abnormality using myelography and computed tomography led to prompt surgical decompression resulting in improvement of the patient's condition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883219

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Subarachnoid Techniques for Cancer Pain Therapy: When, Why, and How?

Authors: 
Journal:  Curr Rev Pain       Date:  1999

2.  [Dangers and complications in pain therapy with epidural and intrathecal catheters.].

Authors:  B Donner; M Tryba; M Strumpf; R Dertwinkel
Journal:  Schmerz       Date:  1995-10       Impact factor: 1.107

3.  The Infusaid pump in the management of intractable cancer pain.

Authors:  D D Bryant; R L DeWitty; G C Dennis
Journal:  J Natl Med Assoc       Date:  1987-03       Impact factor: 1.798

4.  Optimizing pain control through the use of implantable pumps.

Authors:  Wilfried Ilias; Boris Todoroff
Journal:  Med Devices (Auckl)       Date:  2008-10-21

5.  Spinal cord compression secondary to intrathecal catheter-induced granuloma: a report of four cases.

Authors:  Paul M Arnold; Viraat Harsh; Seth M Oliphant
Journal:  Evid Based Spine Care J       Date:  2011-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.